In order to clarify the mechanism of antiatherogenic action of several steroids such as estrogens, dehydroepiandrosterone (DHEA) and dexamethasone, we investigated the effects of various steroids on the copper (Cu2+)-catalyzed oxidation of low density lipoprotein (LDL) or high density lipoprotein (HDL) in 0.15 M NaCl by measuring thiobarbituric acid-reactive substances (TBARS). At a concentration of 10-5 M, estrogens strongly protected against LDL oxidation by 0.5 uM Cu2+ in the following order of inhibition: estradiol (E2) (75%), estrone (E1) (35%) and estriol (E3) (30%). However, the corresponding metabolites of these estrogens, the catechol estrogens, had an even more protective effect on LDL oxidation by 0.5 iM Cu2+ in the following order of inhibition:
Abstract.
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2-hydroxyestradiol (2-OHE2) (98%), 2-OHE1 (97%) and 2-OHE3 (96%). E2 and 2-OHE2 from 10-7 M to 10-5 M inhibited LDL oxidation in a dose-dependent manner, with a more marked effect for oxidation by 0.1 µM Cu2+ than by 0.5 ,uM Cu2+ . 10-5 M dexamethasone produced a slight (10%) but significant inhibition of LDL oxidation by 0.5 uM Cu2+ . In addition, the estrogens and catechol estrogens were also effective in protecting against HDL oxidation by 0.5 µM Cu2+ . Other steroids including DHEA and DHEA-sulfate had no antioxidative effects on either LDL or HDL in this system. These results indicate that estrogens and their metabolites, the catechol estrogens, exert antioxidative effects on both LDL and HDL. The catechol estrogens may be more important antioxidants than estrogens for both LDL and HDL. Dexamethasone may exert its antiatherogenic effect partly by inhibiting the oxidation of lipoproteins, but this may not be the case for DHEA and DHEA-sulfate. A previous study in cholesterol-fed rabbits has shown that 17-/3 estradiol reduced atherosclerotic plaque formation without any change in cholesterol levels [15] . An antioxidative effect of estrogens on LDL was recently demonstrated in vitro [16] [17] [18] [19] . Furthermore, it has also been shown that the degradation by macrophages of oxidized LDL was markedly reduced by treatment with estrogens [171. These results suggest that an inhibitory effect of estrogens on foam cell formation may be another mechanism for its antiatherogenic action. Dehydroepiandrosterone (DHEA) and dexamethasone have also been shown to be antiatherogenic in cholesterol-fed rabbits [20] [21] [22] [23] , independent of changes in plasma total and LDL cholesterol levels, although the precise mechanism of their antiatherogenic action has not been clarified.
Since previous studies have mainly focused on the antioxidative effects of estrogens on LDL oxidation and have not thoroughly examined the effects of steroids on HDL oxidation, we undertook the present study to test various steroids including catechol estrogens, DHEA and dexamethasone with respect to their ability to inhibit LDL or HDL oxidation catalyzed by copper ions (Cu2+) in vitro. 
Results
Oxidative modification of LDL or HDL in 0.15 M NaCl as measured by TBARS production at 0 to 0.5 ,uM Cu2+ was observed to occur in a dose-de-pendent manner (Fig. 1) . The degree of Cu2+-catalyzed oxidation of HDL was less than that of LDL at the same protein concentration. Fig. 2A shows the effects of various steroids at a concentration of 10-5 M on the oxidative modification of LDL by 0.5 ,uM Cu2+ as measured by TBARS production.
10-5M estrogens strongly protected against LDL oxidation by 0.5 ,uM Cu2+ in the following order of inhibition: estradiol (E2) (75%), estrone (E1) (35%) and estriol (E3) (30%). However, the corresponding metabolites of these estrogens, the catechol estrogens, had an even more protective effect against LDL oxidation by 0.5 ,uM Cu2+ in the following order of inhibition: 2-hydroxyestradiol (2-OHE2) (98%), 2-OHE, (97%) and 2-OHE3 (96%). 10-5 M dexamethasone protected a slight but significant inhibition of LDL oxidation by 10%, whereas other steroids including DHEA, DHEA-sulfate (DHEA-S), testosterone (T) and dihydrotestosterone (DHT) did not inhibit LDL oxidation by 0.5 ,uM Cu2 + . E2 and 2-OHE2 10-7 M to 10-5 M significantly inhibited LDL oxidation in a dose-dependent manner, with a more marked effect for oxidation by 0.1 ,uM Cu2+ than by 0.5 ,uM Cu2+ ( Fig. 3A and 3B) . The more protective effect of 2-OHE2 than E2 against LDL oxidation by 0.1 ,uM Cu2+ was observed in a dose-dependent manner ( Fig. 2A, B) . 10-5 M estrogens and catechol estrogens were also effective in protecting against HDL oxidation by 0.5 ,uM Cu2+ in the following order of inhibition: 2-OHE2 (98%), 2-OHE1 (97%), 2-OHE3 (93%), E2 (86%), E1 (81%) and E3 (78%) (Fig. 2B) . DHEA, DHEA-S, testosterone (T) and dexamethasone 10-5 M were ineffective in inhibiting HDL oxidation by 0.5 ,uM Cu2+. 
Discussion
The oxidative modification of LDL by Cu2+ was significantly protected by E2, E1 and E3, as was recently reported in two other studies [17, 18] . Although E2 was consistently the most potent estrogen acting against LDL oxidation, no protective effect of E1 against Cu2+-catalyzed LDL oxidation was observed by Rifici et al. [18] but was seen by us and by Maziere et al. [17] . This discrepancy is probably due to differences in the Cu2+ concentration used for LDL oxidation. The 0.1-0.5 ,uM Cu2+ concentrations in 0.15 M NaCl in our study were rather low compared with the 5 ,uM Cu2+ in PBS usually used in other studies [17, 18] . More importantly, catechol estrogens, the main metabolites of estrogens, had an even more potent inhibitory effect on LDL oxidation catalyzed by Cu2+ . The [25] . The catechol estrogens, 2-OHE1 and 2-OHE2, could be formed from their corresponding estrogens by estrogen 2-hydroxylase [26] in microsomes in the brain [27] or liver and other tissues [28] . The presence of 2-OHE1 in human plasma [29] and in urine [30] has been reported. Although the biological significance of catechol estrogens is unclear, they possess the phinolic structure and catechols, both of which are known to be strongly antioxidative. Estrogens may therefore exert their antiatherogenic action alone or through their metabolites, the catechol estrogens.
In the present study, the degree of oxidative modification of HDL was relatively weaker than that of LDL at the same protein concentration. Interestingly, an antioxidative effect of lipoprotein containing apoprotein A-I on Cu2+ -catalyzed oxidation of LDL was recently reported [31] . While admittedly such as comparison is not easy because of the big difference between LDL and HDL particle size, the decreased susceptibility of HDL to Cu2+-catalyzed oxidation could partly result from the antioxidative effects of apoprotein A-I, a major apoprotein in HDL. Estrogens and catechol estrogens were similarly effective in inhibiting HDL oxidation by Cu2+, suggesting another important mechanism of the action of estrogens against atherosclerosis, since oxidized HDL has been reported to be less effective if accelerating cholesterol efflux from cholesterol ester-laden cells (foam cells) [12] . Although the concentration of estrogens and catechol estrogens required to inhibit LDL or HDL oxidation in these in vitro experiments was supraphysiological as compared to the physiological concentrations in human (<1.5 nM), we also noted that estrogens were more effective when LDL was subjected to less extensive oxidation by a lower Cu2+ concentration. Therefore, a low but constant level of estrogens may exert its antioxidative effect against minimal or slight oxidation of LDL in vivo. Since esterified estrogens have been found in serum [32] , the integration of the esterified estrogens into lipoprotein particles could stabilize and inhibit against LDL oxidation [18] . Indeed, an increased concentration of serum lipid peroxide after ovalectomies has been reported in mice [33] , suggesting the physiological significance of estrogen action on lipid peroxidation in vivo. DHEA and its sulfate ester, DHEA-S, are weak androgens that are produced primarily by the adrenal gland.
DHEA is thought to be antiatherogenic in humans since the administration of DHEA to normal men reduces their body fat and total and LDL cholesterol levels [34] and since circulating levels of DHEA-S are inversely related to death from cardiovascular disease in men over 50 years of age [35] . Indeed, the administration of DHEA to cholesterol-fed rabbits reduced aortic involvement by fatty streaks, independent of changes in serum lipids [20, 21] . The present study indicates that DHEA or DHEA-S is not antioxidative against LDL or HDL, suggesting a different mechanism for its antiatherogenecity.
A glucocorticoid, dexamethasone, is another steroid that may be antiatherogenic.
While glucocorticoids tend to be atherogenic with respect to lipid metabolism in humans [36] , it has been reported that dietary supplementation with dexamethasone significantly reduces the atherosclerotic changes in cholesterol-fed rabbits despite aggravation of lipid metabolism [23] . 
